Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion

• Status: Completed
• Trial end date: 2020-01-26
• Target enrollment: 0
• Participant gender: All

Summary

Continuous-infusion of piperacillin/tazobactam over 4 hrs instead of 30-minute intermittent dosage regimen has shown observable outcomes. Our objective is to assess whether continuous infusion of piperacillin/tazobactam is superior in terms of efficacy, safety and cost to the intermittent regimen to treat suspected or proved infections due to gram negative bacteria. The setting is Critical Care Medicine Department at Cairo University Hospitals. Methods A prospective randomized comparative study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

Criteria

Inclusion Criteria:

• Adults aged 18-74 years

• Expected ICU stay more than 24 hours

Exclusion Criteria:

• Allergy or potential allergy to the study medications

• Pregnancy

• Patients with CrCl< 20 ml/min or on dialysis

• Cancer patients